SpringWorks Therapeutics Inc. will soon launch its first product after the US Food and Drug Administration approved the small molecule gamma secretase inhibitor Ogsiveo (nirogacestat) for adults with progressing desmoid tumors who require systemic treatment. As the first-ever drug approved to treat the rare tumors, Ogsiveo appears poised to enjoy a warm welcome from doctors and patients who have been searching for alternatives to often ineffective surgeries and off-label medicines.
SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors
Nirogacestat Also In Anti-BCMA Combo, Ovarian Cancer Studies
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.